Literature DB >> 26448657

Ciprofloxacin: Tularemia (Adults).

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2015        PMID: 26448657      PMCID: PMC4589879          DOI: 10.1310/hpj5004-274

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  8 in total

1.  Treatment of tularemia with ciprofloxacin.

Authors:  A Chocarro; A Gonzalez; I Garcia
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

2.  Tularemia after a dormouse bite in Switzerland.

Authors:  A Friedl; I Heinzer; H Fankhauser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

3.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Sheldon L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2014-07-15       Impact factor: 9.079

4.  Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia.

Authors:  Philippe Bossi; Anders Tegnell; Agoritsa Baka; Frank Van Loock; Jan Hendriks; Albrecht Werner; Heinrich Maidhof; Georgios Gouvras
Journal:  Euro Surveill       Date:  2004-12-15

Review 5.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Evolution toward high-level fluoroquinolone resistance in Francisella species.

Authors:  Vivien Sutera; Maxime Levert; Wim Pascal Burmeister; Dominique Schneider; Max Maurin
Journal:  J Antimicrob Chemother       Date:  2013-08-20       Impact factor: 5.790

7.  Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases.

Authors:  Ingrid B Weber; George Turabelidze; Sarah Patrick; Kevin S Griffith; Kiersten J Kugeler; Paul S Mead
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

8.  Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia.

Authors:  Meliha Meric; Ayse Willke; Enrst-Jurgen Finke; Roland Grunow; Murat Sayan; Sarper Erdogan; Suna Gedikoglu
Journal:  APMIS       Date:  2008-01       Impact factor: 3.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.